ARDSLEY, N.Y.--(BUSINESS WIRE)--Results from a large-scale retrospective claims database study assessing real-world use of AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg will be presented by Acorda Therapeutics, Inc. (Nasdaq:ACOR) and HealthCore Inc. at the 2014 Joint ACTRIMS-ECTRIMS Meeting. The study analyzed AMPYRA prescribing patterns, adherence, and budget impact in a managed care setting.
Help employers find you! Check out all the jobs and post your resume.
